BEAM - Beam Therapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BEAM is currently covered by 15 analysts with an average price target of $44.94. This is a potential upside of $26.64 (145.57%) from yesterday's end of day stock price of $18.3.

Beam Therapeutics 's activity chart (see below) currently has 60 price targets and 79 ratings on display. The stock rating distribution of BEAM is 34.88% HOLD and 65.12% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 36.99% with an average time for these price targets to be met of 70.79 days.

Highest price target for BEAM is $80, Lowest price target is $25, average price target is $50.33.

Most recent stock forecast was given by GENA WANG from BARCLAYS on 07-May-2025. First documented stock forecast 02-Mar-2020.

Currently out of the existing stock ratings of BEAM, 15 are a HOLD (34.88%), 28 are a BUY (65.12%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$25

$5.29 (26.84%)

$31

2 months 30 days ago
(07-May-2025)

9/10 (90%)

$8.77 (54.04%)

158

Buy

$55

$35.29 (179.05%)

$78

2 months 30 days ago
(07-May-2025)

0/4 (0%)

$38.77 (238.88%)

Buy

$70

$50.29 (255.15%)

$105

2 months 30 days ago
(07-May-2025)

0/3 (0%)

$53.77 (331.30%)

Buy

$80

$60.29 (305.89%)

$80

3 months 30 days ago
(07-Apr-2025)

0/8 (0%)

$64.7 (422.88%)

Buy

4 months 25 days ago
(12-Mar-2025)

1/10 (10%)

$12.38 (46.51%)

118

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BEAM (Beam Therapeutics ) average time for price targets to be met?

On average it took 70.79 days on average for the stock forecasts to be realized with a an average price target met ratio 36.99

Which analyst has the current highest performing score on BEAM (Beam Therapeutics ) with a proven track record?

DAVID NIERENGARTEN

Which analyst has the most public recommendations on BEAM (Beam Therapeutics )?

David Nierengarten works at WEDBUSH and has 8 price targets and 5 ratings on BEAM

Which analyst is the currently most bullish on BEAM (Beam Therapeutics )?

Patrick Trucchio with highest potential upside - $60.29

Which analyst is the currently most reserved on BEAM (Beam Therapeutics )?

Rick Bienkowski with lowest potential downside - -$0

Beam Therapeutics  in the News

PBF Energy declares $0.275 dividend

* PBF Energy (NYSE:PBF [https://seekingalpha.com/symbol/PBF]) declares $0.275/share quarterly dividend [https://seekingalpha.com/pr/20184218-pbf-energy-announces-second-quarter-2025-results-and-declares-dividend-of-0_275-per-share], in line with previous. * Forward yield [https://seekingalpha.com/symbol/PBF/dividends/yield?source=news_bullet] 4.47% * Payable Aug. 28; for shareholders of record Aug. 14; ex-div Aug. 14. * See PBF Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/PBF/dividends?source=news_bullet] MORE ON PBF ENERGY * PBF Energy: No Longer Bleeding Cash After...

Cathie Wood's ARK ETF bolsters Beam stock, sheds Roblox

Cathie Wood’s ARK ETF published their daily trades for Monday, July 7th, 2025, revealing a continued interest in genomics with a significant investment in Beam Therapeutics Inc (NASDAQ:BEAM), while reducing positions in several other companies. The trades executed by ARK indicate ongoing strategic adjustments to their portfolio, aligning with the firm’s innovative investment philosophy. The...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?